Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2020

Purpose The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2020.Materials and Methods Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Databa...

Full description

Saved in:
Bibliographic Details
Published inCancer research and treatment Vol. 55; no. 2; pp. 385 - 399
Main Authors Kang, Mee Joo, Jung, Kyu-Won, Bang, So Hyun, Choi, Seo Hyun, Park, Eun Hye, Yun, E Hwa, Kim, Hye-Jin, Kong, Hyun-Joo, Im, Jeong-Soo, Seo, Hong Gwan
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Cancer Association 01.04.2023
대한암학회
Subjects
Online AccessGet full text
ISSN1598-2998
2005-9256
2005-9256
DOI10.4143/crt.2023.447

Cover

Abstract Purpose The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2020.Materials and Methods Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2020, with survival follow-up until December 31, 2021. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea.Results The number of new cancer diagnoses in 2020 decreased by 9,218 cases (3.6%) compared to 2019. In 2020, newly diagnosed cancer cases and deaths from cancer were reported as 247,952 (age-standardized rate [ASR], 262.2 per 100,000) and 82,204 (ASR, 69.9 per 100,000), respectively. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.0% annually from 2012 to 2015, thereafter, followed by nonsignificant changes. Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years. The 5-year relative survival between 2016 and 2020 was 71.5%, which contributed to prevalent cases reaching over 2.2 million in 2020.Conclusion In 2020, the number of newly diagnosed cancer patients decreased due to the coronavirus disease 2019 pandemic, but the overall trend is on the rise. Cancer survival rates have improved over the past decades. As the number of cancer survivors increases, a comprehensive cancer control strategy should be implemented in line with the changing aspects of cancer statistics. The long-term impact of the coronavirus disease 2019 pandemic on cancer statistics needs to be investigated in the future.
AbstractList Purpose The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2020.Materials and Methods Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2020, with survival follow-up until December 31, 2021. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea.Results The number of new cancer diagnoses in 2020 decreased by 9,218 cases (3.6%) compared to 2019. In 2020, newly diagnosed cancer cases and deaths from cancer were reported as 247,952 (age-standardized rate [ASR], 262.2 per 100,000) and 82,204 (ASR, 69.9 per 100,000), respectively. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.0% annually from 2012 to 2015, thereafter, followed by nonsignificant changes. Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years. The 5-year relative survival between 2016 and 2020 was 71.5%, which contributed to prevalent cases reaching over 2.2 million in 2020.Conclusion In 2020, the number of newly diagnosed cancer patients decreased due to the coronavirus disease 2019 pandemic, but the overall trend is on the rise. Cancer survival rates have improved over the past decades. As the number of cancer survivors increases, a comprehensive cancer control strategy should be implemented in line with the changing aspects of cancer statistics. The long-term impact of the coronavirus disease 2019 pandemic on cancer statistics needs to be investigated in the future.
The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2020.PURPOSEThe current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2020.Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2020, with survival follow-up until December 31, 2021. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea.Materials and MethodsIncidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2020, with survival follow-up until December 31, 2021. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea.The number of new cancer diagnoses in 2020 decreased by 9,218 cases (3.6%) compared to 2019. In 2020, newly diagnosed cancer cases and deaths from cancer were reported as 247,952 (age-standardized rate [ASR], 262.2 per 100,000) and 82,204 (ASR, 69.9 per 100,000), respectively. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.0% annually from 2012 to 2015, thereafter, followed by nonsignificant changes. Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years. The 5-year relative survival between 2016 and 2020 was 71.5%, which contributed to prevalent cases reaching over 2.2 million in 2020.RESULTSThe number of new cancer diagnoses in 2020 decreased by 9,218 cases (3.6%) compared to 2019. In 2020, newly diagnosed cancer cases and deaths from cancer were reported as 247,952 (age-standardized rate [ASR], 262.2 per 100,000) and 82,204 (ASR, 69.9 per 100,000), respectively. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.0% annually from 2012 to 2015, thereafter, followed by nonsignificant changes. Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years. The 5-year relative survival between 2016 and 2020 was 71.5%, which contributed to prevalent cases reaching over 2.2 million in 2020.In 2020, the number of newly diagnosed cancer patients decreased due to the coronavirus disease 2019 pandemic, but the overall trend is on the rise. Cancer survival rates have improved over the past decades. As the number of cancer survivors increases, a comprehensive cancer control strategy should be implemented in line with the changing aspects of cancer statistics. The long-term impact of the coronavirus disease 2019 pandemic on cancer statistics needs to be investigated in the future.CONCLUSIONIn 2020, the number of newly diagnosed cancer patients decreased due to the coronavirus disease 2019 pandemic, but the overall trend is on the rise. Cancer survival rates have improved over the past decades. As the number of cancer survivors increases, a comprehensive cancer control strategy should be implemented in line with the changing aspects of cancer statistics. The long-term impact of the coronavirus disease 2019 pandemic on cancer statistics needs to be investigated in the future.
Purpose The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2020. Materials and Methods Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2020, with survival follow-up until December 31, 2021. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea. Results The number of new cancer diagnoses in 2020 decreased by 9,218 cases (3.6%) compared to 2019. In 2020, newly diagnosed cancer cases and deaths from cancer were reported as 247,952 (age-standardized rate [ASR], 262.2 per 100,000) and 82,204 (ASR, 69.9 per 100,000), respectively. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.0% annually from 2012 to 2015, thereafter, followed by nonsignificant changes. Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years. The 5-year relative survival between 2016 and 2020 was 71.5%, which contributed to prevalent cases reaching over 2.2 million in 2020. Conclusion In 2020, the number of newly diagnosed cancer patients decreased due to the coronavirus disease 2019 pandemic, but the overall trend is on the rise. Cancer survival rates have improved over the past decades. As the number of cancer survivors increases, a comprehensive cancer control strategy should be implemented in line with the changing aspects of cancer statistics. The long-term impact of the coronavirus disease 2019 pandemic on cancer statistics needs to be investigated in the future. KCI Citation Count: 15
The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2020. Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2020, with survival follow-up until December 31, 2021. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea. The number of new cancer diagnoses in 2020 decreased by 9,218 cases (3.6%) compared to 2019. In 2020, newly diagnosed cancer cases and deaths from cancer were reported as 247,952 (age-standardized rate [ASR], 262.2 per 100,000) and 82,204 (ASR, 69.9 per 100,000), respectively. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.0% annually from 2012 to 2015, thereafter, followed by nonsignificant changes. Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years. The 5-year relative survival between 2016 and 2020 was 71.5%, which contributed to prevalent cases reaching over 2.2 million in 2020. In 2020, the number of newly diagnosed cancer patients decreased due to the coronavirus disease 2019 pandemic, but the overall trend is on the rise. Cancer survival rates have improved over the past decades. As the number of cancer survivors increases, a comprehensive cancer control strategy should be implemented in line with the changing aspects of cancer statistics. The long-term impact of the coronavirus disease 2019 pandemic on cancer statistics needs to be investigated in the future.
Author Kang, Mee Joo
Park, Eun Hye
Kim, Hye-Jin
Jung, Kyu-Won
Bang, So Hyun
Yun, E Hwa
Seo, Hong Gwan
Kong, Hyun-Joo
Choi, Seo Hyun
Im, Jeong-Soo
AuthorAffiliation Korea Central Cancer Registry, National Cancer Center, Goyang, Korea
AuthorAffiliation_xml – name: Korea Central Cancer Registry, National Cancer Center, Goyang, Korea
– name: 1 Korea Central Cancer Registry, National Cancer Center, Goyang, Korea
– name: 3 National Cancer Control Institute, National Cancer Center, Goyang, Korea
– name: 4 National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea
– name: 2 Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, Korea
Author_xml – sequence: 1
  givenname: Mee Joo
  surname: Kang
  fullname: Kang, Mee Joo
– sequence: 2
  givenname: Kyu-Won
  surname: Jung
  fullname: Jung, Kyu-Won
– sequence: 3
  givenname: So Hyun
  surname: Bang
  fullname: Bang, So Hyun
– sequence: 4
  givenname: Seo Hyun
  surname: Choi
  fullname: Choi, Seo Hyun
– sequence: 5
  givenname: Eun Hye
  surname: Park
  fullname: Park, Eun Hye
– sequence: 6
  givenname: E Hwa
  surname: Yun
  fullname: Yun, E Hwa
– sequence: 7
  givenname: Hye-Jin
  surname: Kim
  fullname: Kim, Hye-Jin
– sequence: 8
  givenname: Hyun-Joo
  surname: Kong
  fullname: Kong, Hyun-Joo
– sequence: 9
  givenname: Jeong-Soo
  surname: Im
  fullname: Im, Jeong-Soo
– sequence: 10
  givenname: Hong Gwan
  surname: Seo
  fullname: Seo, Hong Gwan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36915245$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002948880$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNptkU1PGzEQhi0EKoH21nO1x6rKpvb4a90LQhHQCKpWfJwtx3GKy8amthOJf4-XUFSqyofxaJ55Z-z3AO2GGBxC7wmeMMLoZ5vKBDDQCWNyB40AY94q4GIXjQhXXQtKdfvoIOdfGAtGJXmD9qlQhAPjI3Q5NcG61FwVU3wu3ubGh-Y8Jme-NLNg_cLV-rj5FlMxvS8P4-ZqnTZ-Y_pxY8Ki-ZFcvQ_Q0FgXwW_R3tL02b17jofo5vTkevq1vfh-NpseX7SWAS6tUUwyACJg3i1BSiaNAYm5Erw-C9cUCwWC22FZCoRSBXTOrATFTQeOHqJPW92QlvrOeh2Nf4o_o75L-vjyeqYJBsIIpxU-2sL36_nKLawLJZle3ye_MunhqfV1JfjbKrSpCvVIJarCx2eFFH-vXS565bN1fW-Ci-usQXaiI7TjXUU__D3sZcqfb6_AeAvYFHNObvmCEKwHV3V1VQ-u6upqxeEf3PrBrzis6vv_Nz0CH1WhfA
CitedBy_id crossref_primary_10_1186_s12888_025_06602_z
crossref_primary_10_25055_JKSRNT_2024_15_2_49
crossref_primary_10_1186_s12885_025_13513_5
crossref_primary_10_3390_nu16071048
crossref_primary_10_3389_fonc_2024_1403120
crossref_primary_10_1007_s00520_024_08341_5
crossref_primary_10_17998_jlc_2024_08_13
crossref_primary_10_1002_ijc_34935
crossref_primary_10_15279_kpba_2023_28_4_131
crossref_primary_10_1245_s10434_024_16792_7
crossref_primary_10_1016_j_nutres_2024_09_003
crossref_primary_10_3390_cancers15235606
crossref_primary_10_1007_s00330_025_11461_z
crossref_primary_10_1016_j_apjon_2024_100483
crossref_primary_10_4166_kjg_2024_091
crossref_primary_10_1016_j_heliyon_2024_e37046
crossref_primary_10_5468_ogs_23208
crossref_primary_10_3390_cimb47020088
crossref_primary_10_3390_cancers16162923
crossref_primary_10_3390_healthcare11243171
crossref_primary_10_1016_j_prnil_2024_12_002
crossref_primary_10_21032_jhis_2023_48_S1_S15
crossref_primary_10_3346_jkms_2024_39_e320
crossref_primary_10_5534_wjmh_230104
crossref_primary_10_12771_emj_2024_e53
crossref_primary_10_22465_juo_234600480024
crossref_primary_10_3892_ol_2024_14668
crossref_primary_10_22465_juo_244600220011
crossref_primary_10_5009_gnl240111
crossref_primary_10_4111_icu_20230333
crossref_primary_10_3857_roj_2023_00955
crossref_primary_10_1007_s00520_024_08347_z
crossref_primary_10_1016_j_esmoop_2024_103969
crossref_primary_10_4178_epih_e2023101
crossref_primary_10_3390_electronics14050880
crossref_primary_10_5124_jkma_2024_67_7_484
crossref_primary_10_1109_ACCESS_2023_3296710
crossref_primary_10_4174_astr_2023_105_6_376
crossref_primary_10_3389_fonc_2024_1395473
crossref_primary_10_4143_crt_2024_207
crossref_primary_10_1007_s13187_024_02502_0
crossref_primary_10_3947_ic_2024_0057
crossref_primary_10_3390_cancers15133371
crossref_primary_10_5853_jos_2023_03279
crossref_primary_10_1007_s10549_024_07571_9
crossref_primary_10_1007_s11764_024_01642_y
crossref_primary_10_3389_fpubh_2023_1256525
crossref_primary_10_3390_cancers15164134
crossref_primary_10_1111_joim_20071
crossref_primary_10_1016_j_jtho_2024_12_006
crossref_primary_10_3390_ijms241814355
crossref_primary_10_52927_jdcr_2024_12_2_53
crossref_primary_10_1016_j_canep_2024_102594
crossref_primary_10_4143_crt_2024_325
crossref_primary_10_1016_j_radonc_2023_109982
crossref_primary_10_1016_j_puhe_2024_11_015
crossref_primary_10_1080_09637486_2024_2314678
crossref_primary_10_3349_ymj_2023_0009
crossref_primary_10_4132_jptm_2024_07_29
crossref_primary_10_1007_s00520_025_09169_3
crossref_primary_10_1177_17588359241254218
crossref_primary_10_3892_mi_2025_214
crossref_primary_10_4178_epih_e2023089
crossref_primary_10_1016_j_ejso_2024_108515
crossref_primary_10_1016_j_diagmicrobio_2024_116433
crossref_primary_10_1038_s41598_024_83048_5
crossref_primary_10_1017_S1478951523001815
crossref_primary_10_3904_kjm_2024_99_2_96
crossref_primary_10_1002_cam4_6660
crossref_primary_10_4111_icu_20240047
crossref_primary_10_3349_ymj_2023_0014
crossref_primary_10_1016_j_pec_2025_108674
crossref_primary_10_1158_1940_6207_CAPR_24_0154
crossref_primary_10_1017_S000711452400206X
crossref_primary_10_4178_epih_e2023077
crossref_primary_10_1007_s13258_023_01408_3
crossref_primary_10_21593_kjhno_2023_39_1_1
crossref_primary_10_1097_MD_0000000000037639
crossref_primary_10_4143_crt_2024_421
crossref_primary_10_3390_cancers15235516
crossref_primary_10_5977_jkasne_2024_30_3_290
crossref_primary_10_3348_kjr_2024_0866
crossref_primary_10_1002_cncr_35711
crossref_primary_10_1016_j_ygyno_2024_09_015
crossref_primary_10_3390_cancers16132486
crossref_primary_10_4178_epih_e2024074
crossref_primary_10_1177_16094069241247476
crossref_primary_10_15747_ACNM_2024_16_1_10
crossref_primary_10_3390_cancers16244278
crossref_primary_10_52927_jdcr_2024_12_2_82
crossref_primary_10_15747_ACNM_2024_16_2_66
crossref_primary_10_4143_crt_2024_016
crossref_primary_10_4174_astr_2024_107_2_59
crossref_primary_10_11106_ijt_2023_16_2_143
crossref_primary_10_1002_cam4_70030
crossref_primary_10_1097_MD_0000000000037732
crossref_primary_10_1200_GO_23_00352
crossref_primary_10_3393_ac_2024_00388_0055
crossref_primary_10_4174_astr_2025_108_1_20
crossref_primary_10_3390_jpm14101058
crossref_primary_10_1111_jgh_16493
crossref_primary_10_3904_kjm_2023_98_6_283
crossref_primary_10_1038_s41598_024_75493_z
crossref_primary_10_3390_cancers15225414
crossref_primary_10_3390_medicina60091509
crossref_primary_10_11620_IJOB_2024_49_1_18
crossref_primary_10_4093_dmj_2024_0277
crossref_primary_10_1038_s41598_025_92951_4
crossref_primary_10_3390_cancers15245809
crossref_primary_10_1016_j_heliyon_2024_e28121
crossref_primary_10_1038_s41416_024_02847_9
crossref_primary_10_51666_fs_2023_3_e5
crossref_primary_10_1186_s12885_023_11736_y
crossref_primary_10_22465_juo_234600560028
crossref_primary_10_1186_s12885_025_13819_4
Cites_doi 10.4143/crt.2005.37.6.325
10.1038/s41598-022-15778-3
10.1001/jamaoncol.2022.2617
10.3322/caac.21708
ContentType Journal Article
Copyright Copyright © 2023 by the Korean Cancer Association 2023
Copyright_xml – notice: Copyright © 2023 by the Korean Cancer Association 2023
CorporateAuthor The Community of Population-Based Regional Cancer Registries
Community of Population-Based Regional Cancer Registries
CorporateAuthor_xml – name: The Community of Population-Based Regional Cancer Registries
– name: Community of Population-Based Regional Cancer Registries
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ACYCR
DOI 10.4143/crt.2023.447
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2005-9256
EndPage 399
ExternalDocumentID oai_kci_go_kr_ARTI_10214153
PMC10101796
36915245
10_4143_crt_2023_447
Genre Journal Article
GeographicLocations Republic of Korea
GeographicLocations_xml – name: Republic of Korea
GrantInformation_xml – fundername: Ministry of Health and Welfare
  grantid: 2260020
– fundername: National Cancer Center
  grantid: 2211110
– fundername: Health Promotion Fund of the Ministry of Health & Welfare
  grantid: 2260020; 2211110
– fundername: National Cancer Center, Republic of Korea
GroupedDBID ---
29B
5-W
53G
8JR
9ZL
AAYXX
ABDBF
ACUHS
ACYCR
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
E3Z
EBD
EF.
F5P
HYE
OK1
RPM
TR2
C1A
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
M~E
ID FETCH-LOGICAL-c420t-a947422162b8f27747aa2705965143047a069265c369132133923b4c7295a82e3
ISSN 1598-2998
2005-9256
IngestDate Sat Apr 06 03:24:33 EDT 2024
Thu Aug 21 18:38:04 EDT 2025
Thu Jul 10 22:52:38 EDT 2025
Mon Jul 21 05:54:09 EDT 2025
Thu Apr 24 23:10:15 EDT 2025
Tue Jul 01 03:18:52 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Prevalence
Survival
Mortality
Neoplasms
Incidence
Korea
Language English
License This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c420t-a947422162b8f27747aa2705965143047a069265c369132133923b4c7295a82e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Regional Cancer Registry Committee
Chang-Hoon Kim (Busan Cancer Registry, Pusan National University Hospital), Cheol-In Yoo (Ulsan Cancer Registry, Ulsan University Hospital), Yong-Dae Kim (Chungbuk Cancer Registry, Chungbuk National University Hospital), Young-Taek Kim (Daejeon/Chungnam Cancer Registry, Chungnam National University and Hospital), Chul Min Park (Jeju Cancer Registry, Jeju National University and Hospital), Jung-Ho Youm (Chonbuk Cancer Registry, Jeonbuk National University Hospital), Kyu-Hyoung Lim (Kangwon Cancer Registry, Kangwon National University and Hospital), Nam-Soo Hong (Daegu/Gyeongbuk Cancer Registry, Kyungpook National University), Sun-Seog Kweon (Gwangju/Jeonnam Cancer Registry, Chonnam National University Hwasun Hospital), Woo-Chul Kim (Incheon Cancer Registry, Inha University Hospital), Ki-Soo Park (Gyeongnam Cancer Registry, Gyeongsang National University and Hospital).
ORCID 0000-0002-4389-9701
0000-0002-9289-3808
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC10101796
PMID 36915245
PQID 2786813858
PQPubID 23479
PageCount 15
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_10214153
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10101796
proquest_miscellaneous_2786813858
pubmed_primary_36915245
crossref_primary_10_4143_crt_2023_447
crossref_citationtrail_10_4143_crt_2023_447
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-04-01
PublicationDateYYYYMMDD 2023-04-01
PublicationDate_xml – month: 04
  year: 2023
  text: 2023-04-01
  day: 01
PublicationDecade 2020
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Cancer research and treatment
PublicationTitleAlternate Cancer Res Treat
PublicationYear 2023
Publisher Korean Cancer Association
대한암학회
Publisher_xml – name: Korean Cancer Association
– name: 대한암학회
References Fritz (ref8) 2013
(ref2) 2021
Young (ref12) 2001
Ferlay (ref1) 2020
Ajiki (ref7) 1998
(ref9) 1994
ref4
Ferlay (ref10) 2020
ref3
(ref11) 2017
ref6
Segi (ref14) 1960
ref5
(ref13) 2017
(ref16) 2016
Ederer (ref15) 1959
References_xml – year: 2017
  ident: ref13
– year: 2020
  ident: ref1
– year: 2017
  ident: ref11
– year: 1960
  ident: ref14
– ident: ref6
  doi: 10.4143/crt.2005.37.6.325
– year: 2020
  ident: ref10
– volume-title: SEER summary staging manual 2000: codes and coding instructions
  year: 2001
  ident: ref12
– ident: ref4
  doi: 10.1038/s41598-022-15778-3
– year: 2016
  ident: ref16
– year: 2021
  ident: ref2
– ident: ref5
  doi: 10.1001/jamaoncol.2022.2617
– year: 2013
  ident: ref8
– year: 1994
  ident: ref9
– ident: ref3
  doi: 10.3322/caac.21708
– start-page: 1011
  volume-title: Index for evaluating completeness of registration in population-based cancer registries and estimation of registration rate at the Osaka Cancer Registry between 1966 and 1992 using this index
  year: 1998
  ident: ref7
– year: 1959
  ident: ref15
SSID ssj0064371
Score 2.6029043
Snippet Purpose The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in...
The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2020....
The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 385
SubjectTerms COVID-19 - epidemiology
Humans
Incidence
Neoplasms
Prevalence
Republic of Korea - epidemiology
Special
Survival Rate
의학일반
Title Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2020
URI https://www.ncbi.nlm.nih.gov/pubmed/36915245
https://www.proquest.com/docview/2786813858
https://pubmed.ncbi.nlm.nih.gov/PMC10101796
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002948880
Volume 55
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Cancer Research and Treatment, 2023, 55(2), , pp.385-399
journalDatabaseRights – providerCode: PRVEBS
  databaseName: EBSCOhost Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 2005-9256
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064371
  issn: 1598-2998
  databaseCode: ABDBF
  dateStart: 20120301
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2005-9256
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064371
  issn: 1598-2998
  databaseCode: DIK
  dateStart: 20040101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVERR
  databaseName: KoreaMed Open Access
  customDbUrl:
  eissn: 2005-9256
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064371
  issn: 1598-2998
  databaseCode: 5-W
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://koreamed.org/journals
  providerName: Korean Association of Medical Journal Editors
– providerCode: PRVAQN
  databaseName: PubMed Central (WRLC)
  customDbUrl:
  eissn: 2005-9256
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064371
  issn: 1598-2998
  databaseCode: RPM
  dateStart: 20040101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELe6TkK8IL7p-FAQ8NSmSxzHSXhbC1MBlQe2ib1ZieuyaiiZSoM03vm_ubMdN62KNHjph2vHSn-X85199ztCXs_oTALsuc9nReCzPAA9CAutH2dMBmlRzDOdPjb9zCdn7ON5fN7p_G5FLdWrYih_7cwr-R9UoQ1wxSzZf0DWXRQa4DPgC6-AMLzeCOMxQrbUBqPlW16U_U8V2IHo6MOjbyqG6k1PbWbbEgAnNSiIn5rq32YLIOm3fsbhAjSgQdtmtbNYWiCTCefi053CtvvOU4WpZpULzGl0yXXtf12f-I-aXeqqP7muXfP4otLBBSeq1W63JGjUimSxWjTD1A5TXnqodJumPM2oYRFvVK9h6LUiRlt6NDJ1fOySHJkaStvanoGtBxDJJcbE0mjIDHfnJqn21mLnQhDB-cHxAkYLHC1g9B7ZpwnntEv2j0bvRsfNko6Hm4Z4196XyaDA8Yft2Tdsm71yOd_ltmxH37bMmdO75I71Q7wjI1T3SEeV98mtqY20eEC-GNS9tWx5i9LTsvXWc5I18JxcDbxGqgYeSIi3likciDL1kJwdvz8dT3xbf8OXjAYrP89YwigNOS3SOQU_IclzmmC9JrSyA_ga8IzyWEY8CyMaRmBrRwWT4K_FeUpV9Ih0y6pUT4iXKugzi9V8Dh4wS5IU97rkLOJKqSRUskf6zT8npCWnxxop38UunHrkjet9ZUhZ_tLvFYAgLuVCIIs6vn-rxOVSgK_4Qeii9rDg98jLBiQBuhUPzPJSVfUPQZOUpyEenffIYwOamw_vOaYs7pF0A07XAWfc_KVcXGj-9jDQ6yA_uOFtPCW310_ZM9JdLWv1HEzhVfHCCuofJ7mt0w
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cancer+Statistics+in+Korea%3A+Incidence%2C+Mortality%2C+Survival%2C+and+Prevalence+in+2020&rft.jtitle=Cancer+research+and+treatment&rft.au=Kang%2C+Mee+Joo&rft.au=Jung%2C+Kyu-Won&rft.au=Bang%2C+So+Hyun&rft.au=Choi%2C+Seo+Hyun&rft.date=2023-04-01&rft.issn=1598-2998&rft.eissn=2005-9256&rft.volume=55&rft.issue=2&rft.spage=385&rft.epage=399&rft_id=info:doi/10.4143%2Fcrt.2023.447&rft.externalDBID=n%2Fa&rft.externalDocID=10_4143_crt_2023_447
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1598-2998&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1598-2998&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1598-2998&client=summon